| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 546273100 |
Polycyclo ring system having the 1,3-diazole ring as one of the cyclos
| 88 |
| 546274700 |
Nitrogen or -C(=X)-, wherein X is chalcogen, attached directly to the 1,3-diazole diazole ring by nonionic bonding | 4 |
| 20110313167 | Substituted Heterocycles as Therapeutic agents for treating cancer - MDM2 and MDM4 proteins prevent apoptosis of cancer cells by negatively regulating the transcription factor p53. Compounds according to Formula I | 12-22-2011 |
| 20150368227 | PROCESS FOR THE PREPARATION OF POLYMORPHS OF IMIDACLOPRID - A process for the preparation of a Form I crystalline polymorph of imidacloprid, including: (i) dissolving imidacloprid in an appropriate amount of aqueous solvent or mixture of solvents to obtain an aqueous solution; (ii) cooling the aqueous solution slowly, thereby forming crystals of polymorph Form I of imidacloprid; (iii) isolating the crystals. A process for the preparation of a Form II crystalline polymorph of imidacloprid, comprising: dissolving imidacloprid in an appropriate amount of non-aqueous solvent or mixture of non-aqueous solvents to obtain a non-aqueous solution; (ii) cooling the solution rapidly, thereby forming crystals of polymorph Form II of imidacloprid; (iii) isolating the crystals | 12-24-2015 |
| 20160060246 | PROCESS FOR THE PREPARATION OF POLYMORPHS OF IMIDACLOPRID - A process for the preparation of a Form I crystalline polymorph of imidacloprid, including: (i) dissolving imidacloprid in an appropriate amount of aqueous solvent or mixture of solvents to obtain an aqueous solution; (ii) cooling the aqueous solution slowly, thereby forming crystals of polymorph Form I of imidacloprid; (iii) isolating the crystals. A process for the preparation of a Form II crystalline polymorph of imidacloprid , comprising: dissolving imidacloprid in an appropriate amount of non-aqueous solvent or mixture of non-aqueous solvents to obtain a non-aqueous solution; (ii) cooling the solution rapidly, thereby forming crystals of polymorph Form II of imidacloprid; (iii) isolating the crystals | 03-03-2016 |
| 20160130232 | 4-ALKYNYL IMIDAZOLE DERIVATIVE AND MEDICINE COMPRISING SAME AS ACTIVE INGREDIENT - There are provided 4-alkynylimidazole derivatives represented by the following general formula (I) or phamaceutically acceptable salts thereof; the derivatives have a superior EP4 receptor antagonistic action and are useful as pharmaceuticals for the treatment of diseases associated with the EP4 receptor, for example, as anti-inflammatory and/or analgesic drugs for inflammatory diseases and diseases that involve various kinds of pains, and further as pharmaceuticals for the treatment of immune diseases that result from inflammations as evoked by tissue destruction due to the activation of Th1 cells and/or Th17 cells: | 05-12-2016 |
| 546274100 |
The 1,3-diazole ring is bonded directly to the six-membered hetero ring | 3 |
| 20110218340 | 2-[1-Cyanopropyl)Carbamoyl]-5-Chloromethyl Nicotinic Acids and the Use Thereof in Manufacturing Herbicidal Imidazolinones - 2-[(1-cyanopropyl)carbamoyl]-5-chloromethyl nicotinic acids of formula (I) where Z is hydrogen or halogen; Z | 09-08-2011 |
| 20110245506 | Process for Manufacturing Substituted 5-Methoxymethylpyridine-2,3-Dicarboxylic Acid Derivatives - A process for manufacturing a 2,3-disubstituted-5-methoxymethylpyridine of formula (I), where Z is H or halogen; Z | 10-06-2011 |
| 20130066081 | IMIDAZOLONE-CHALCONE DERIVATIVES AS POTENTIAL ANTICANCER AGENT AND PROCESS FOR THE PREPARATION THEREOF - The present invention provides Chalcone linked Imidazolone compounds of formula A as anti cancer agent against fifty three human cancer cell lines. | 03-14-2013 |
| 546275100 |
Chalcogen attached indirectly to the 1,3-diazole ring by acyclic nonionic bonding | 3 |
| 20110152530 | METHODS OF PREPARING FACTOR XA INHIBITORS AND SALTS THEREOF - The present invention provides for methods of preparing compounds of Formula I or a salt of the compound or a hydrate of the compound or salt thereof that are factor Xa inhibitors. | 06-23-2011 |
| 20120245358 | PROCESS FOR THE PREPARATION OF A COMPOUND USEFUL AS AN INHIBITOR OF TAFIA - The present invention relates to a process for the preparation of a compound of the formula I, | 09-27-2012 |
| 20130245274 | Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives - The present invention relates to a process for the preparation of a compound of the formula I, | 09-19-2013 |
| 546274400 |
Chalcogen attached directly to the 1,3-diazole ring by nonionic bonding | 2 |
| 20090264659 | SALTS OF BENZIMIDAZOLE DERIVATIVE WITH AMINES AND PROCESS FOR MANUFACTURING THE SAME - It is an object of the present invention to provide (1) a process for manufacturing alkali metal salts of 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole which are useful as gastric acid secretion inhibitors, anti-ulcer agents and other drugs and (2) salts of 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole with amines which are intermediates for the production of the alkali metal salts, and a process for manufacturing the same. According to the present invention, disclosed are salts represented by the following formula (I): | 10-22-2009 |
| 20110009637 | Crystals of Dexlansoprazole - The present invention relates to crystals of the Active Pharmaceutical Ingredient (API) Dexlansoprazole, including methods of making the crystals, pharmaceutical compositions comprising the crystals, and methods of treating a patient with the crystals. | 01-13-2011 |
